Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. - Wikidata - awgldk - TriplyDB

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

http://www.wikidata.org/entity/Q35791105

about

Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206.New therapeutic targets in soft tissue sarcoma.Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Molecular profiling of childhood cancer: Biomarkers and novel therapies Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Cell survival and metastasis regulation by Akt signaling in colorectal cancer Rapid screening of novel agents for combination therapy in sarcomas Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.P53 suppresses ribonucleotide reductase via inhibiting mTORC1.MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma.

P2860

Q33685874-DF53FF65-6888-4EC6-BF6B-8463E895B01A Q33992871-2E20349A-FC0D-48C9-8E76-5A990E11A0F1 Q34267924-9C8FC112-F455-4B0D-B365-FCB5E442DEC0 Q34592429-1312DED3-D04A-4D36-980D-8A52FE050BB2 Q35085839-1723C7BF-17C9-4DB1-AF41-E8336A0144D5 Q35104869-879B235B-F7D0-455E-BD60-1C8C93BD7C8A Q35684517-04CF6D13-C4A2-4BE7-9CE7-580EE8523966 Q35767389-1E3A802E-E04C-49EE-8AEE-413E00CB0437 Q36250783-10530F0D-8D95-47B5-AD76-CD3CF3454458 Q36386881-6CFDBB62-01DD-4290-9AE4-4D2C2226723F Q36888962-75D76B26-6AA9-41E0-9819-217D2F03A47F Q36938826-74282DE7-988C-40DE-B2F1-8485CEE812F0 Q37298877-81830E1E-DD99-49BB-94DF-98C2CCF69BFB Q37707078-F5BA462D-598D-46E1-8C22-151C00617947 Q38379348-A973FD22-3195-4E44-B69C-CF5E5CD11E43 Q38784684-2619E88F-009F-468B-9FD2-F9667BE15EC2 Q38862452-9D3B145B-4BCF-45EE-80A1-9FEC860E93D1 Q39326887-447FE194-43A6-4496-8FA3-58254E17E00E Q41628138-2514122F-00A7-4678-98CC-0EA402F2074F Q41764229-4316C7BA-22CE-4B26-8277-BD407338D204 Q43082946-711955DD-3F8A-49B5-8F8F-CB8C3FC2C706

P2860

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

http://www.wikidata.org/entity/Q35791105

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@ast

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@en

type

label

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@ast

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@en

prefLabel

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@ast

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

@en

P1433

Q35791105-922DEC4A-2384-4ACB-9EAF-B9FE018E9F11

P1476

Q35791105-B9C9924E-D4DE-4FE7-9F39-928E6C1187D9

P2093

Q35791105-0E454BB3-9542-41CA-95BC-4F686EA0A8DB

Q35791105-2F8A8345-6D16-4928-B08E-F173EBB7FCFC

Q35791105-2FD9EF0C-0FF2-4F6D-BBCC-F9434A6A5498

Q35791105-3996DAD1-33AF-44D6-BAF7-9326BFD63808

Q35791105-583ACA06-9985-43A6-8135-0A91B0214656

Q35791105-8BBC7491-F9BA-4488-A0C2-72F3EC9CB5BE

Q35791105-E7771623-5AA1-4F58-90C6-81093B86BB08

Q35791105-F2FC17E8-37EA-48B6-9F0E-C73223E9F30A

P2860

Q35791105-17DA94EA-1DB0-4B5E-9D61-30E9D985A460

Q35791105-200407E0-44D8-4C22-AF13-8EE915281FFF

Q35791105-22364A19-FE4D-49C5-BF10-CDCCBADA6D20

Q35791105-22405F40-D3BD-4D1A-B2F6-C60EC64E7037

Q35791105-2480AF83-8247-4982-A208-27C3B96E32CA

Q35791105-2B34A0C3-D75F-4ACA-8CE3-813618C4EB4F

Q35791105-3D89E568-2D86-45DA-88E9-A675EE7B35D2

Q35791105-47F44CD1-1C81-4F23-8368-F94B3390DF80

Q35791105-494E5FED-BE7A-418E-A71B-396F095E8AD3

Q35791105-4FB05129-2B04-4C65-B950-B26AE97B238A

P304

Q35791105-836E92EB-0A9D-4668-AF18-952DAFD3BDD8

P31

Q35791105-3F0EC152-0E44-48E3-A9EF-ECBB9857E3D8

P356

Q35791105-5C53080D-B56B-4718-AF19-256C52663CB6

P433

Q35791105-7E8E4A78-5F64-4ABD-ADCF-A40EE8ACFBA3

P478

Q35791105-23C452F7-10BC-4D2C-B034-7DB62C195F2F

P50

Q35791105-2E9FEFD1-9D23-4586-8E98-9EFF28B9A103

Q35791105-41DB3169-2218-4604-9475-E3AED17CBC2F

Q35791105-4A9E796D-012F-4A81-B9A1-66DD548B94CC

Q35791105-836F6F9A-C1D0-4B2D-B353-4A76EFB00F89

P577

Q35791105-0387169E-7189-43AF-AE89-53CB2CB1376D

P698

Q35791105-CE0C9413-1252-49A0-A45B-12AE67540C74

P932

Q35791105-24044DEB-DA61-494B-9C83-671DC4667063

P356

P1433

Pediatric Blood & Cancer

P1476

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program

@en

P2093

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Raushan T Kurmasheva

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

AKT/PKB signaling: navigating downstream

Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

Targeting the phosphoinositide 3-kinase pathway in cancer

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.

PI3K-Akt pathway: its functions and alterations in human cancer.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

P304

518-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.23412

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2011-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22102563

http://www.w3.org/2001/XMLSchema#string

P932

3290691

http://www.w3.org/2001/XMLSchema#string